Selected Articles from This Issue
Journal: Clinical Cancer Research (2023)

Highlights| April 03 2023 Selected Articles from This Issue Author & Article Information Online ISSN: 1557-3265 Print ISSN: 1078-0432 ©2023 American Association for Cancer Research2023American Association for Cancer Research Clin Cancer Res (2023) 29 (7): 1161. https://doi.org/10.1158/1078-0432.CCR-29-7-HI Related Content A commentary has been published: Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation A commentary has been published: Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma A commentary has been published: Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma View more A commentary has been published: Application of Genomic Sequencing to Refine Patient Stratification for Adjuvant Therapy in Renal Cell Carcinoma View less See also commentary Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical PresentationLiquid Biopsy of Cerebrospinal Fluid for Glioma Diagnosis Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part SarcomaA Randomized Phase II Trial of Sunitinib or Cediranib in ASPS Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic MelanomaTargeting MDSCs in Melanoma Using ATRA Application of Genomic Sequencing to Refine Patient Stratification for Adjuvant Therapy in Renal Cell CarcinomaGenomics-Based Risk Prediction in Localized RCC Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn Email Tools Icon Tools Get Permissions Cite Icon Cite Search Site Article Versions Icon Versions Version of Record April 3 2023 Citation Selected Articles from This Issue. Clin Cancer Res 1 April 2023; 29 (7): 1161. https://doi.org/10.1158/1078-0432.CCR-29-7-HI Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest Search Advanced Search Alveolar soft part sarcoma (ASPS) is a rare, highly vascular tumor with few treatment options. Prior research suggested treatment with a tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptors (VEGFRs) could benefit ASPS patients. Nguyen and colleagues conducted a randomized clinical trial of potent VEGFR TKIs cediranib and sunitinib in aggressive ASPS. The drugs were well tolerated, and the overall response rate was 6.7% and 7.1% for cediranib and sunitinib, respectively. Most patients had a best response of stable disease (86.7% and 78.6% for cediranib and sunitinib, respectively). The selection of patients with aggressive disease that progressed in the 6 months preceding enrollment may account for the lower objective response rates compared to previous reports. This data indicates that prior TKI therapy does not preclude clinical benefit from subsequent TKI treatments, suggesting that sequential TKI therapy may benefit patients with ASPS. Myeloid-derived suppressor cells (MDSCs) limit the efficacy... You do not currently have access to this content.